Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model

Journal of Experimental Medicine

Volumn 185, Issue 5, 1997, Pages 867-874

  Murray, Henry W ^a   Hariprashad, June ^a   Coffman, Robert L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION RESISTANCE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; GRANULOMA; IMMUNIZATION; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; TH2 CELLS;

EID: 0030932976     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.5.867     Document Type: Article

References (60)

1. Karp, C., T. Wynn, M. Satti, A. Kordofani, F. Hashim, F. Neva, T. Nutman, and D. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Invest. 91:1644-1648.
2. Ghalib, H., M. Piuvezam, Y. Skeily, M. Siddig, F. Hashim, D. Russo, and S. Reed. 1993. Interleukin-10 production correlates with pathology in human Leishmania donovani infections J. Clin. Invest. 92:324-329.
3. Holaday, B., M. de Lima Pompeu, S. Jeronimo, M. Texeira, A. de Queiroz Sousa, A. Vasconcelos, R.D. Pearson, J.S. Abrams, and R.M. Locksley. 1993. Potential role for interleukin 10 in the immunosuppression associated with kalaazar. J. Clin. Invest. 92:2626-2632.
4. Carvalho, E., O. Bacellar, T. Regis, R. Coffman, and S. Reed. 1994. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152: 5949-5956.
5. Raziuddin, S., R. Abdalla, E. El-Awad, and M. Al-Janadi. 1994. Immunoregulatory cytokine production in visceral and cutaneous leishmaniasis. J. Infect. Dis. 170:1037-1040.
6. Cenini, P., N. Benhe, A. Hailu, K. McGinnes, and D. Frommel. 1993. Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J. Infect. Dis. 168:986-993.
7. Holaday, B.J., M. Pompeu, T. Evans, D. Braga, M. Texeira, A. Sousa, M. Sadick, J. Abrams, R. Pearson, and R. Locksley. 1993. Correlates of Leishmania-specific immunity in the clinical spectrum of infection with Leishmania chagasi. J. Infect. Dis. 167:411-417.
8. Carvalho, E.M., A. Barral, D. Pedral-Sampario, M. Barral-Netto, R. Badaro, and H. Rocha. 1992, Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165:535-540.
9. Kenney, R., S. Sundar, D. Sacks, and H. Murray. 1995. Cytokine responses in interferon-gamma monotherapy for kalaazar. Clin. Infect. Dis. 21:781a. (Abstr.)
10. Sundar, S., S.G. Reed, S. Sharma, A. Mehrota, and H.W. Murray. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. In press.
11. Zwingenberger, K., G. Harms, C. Pedrosa, S. Omena, S. Beate, and S. Neifer. 1990. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-γ production. Clin. Immunol. Immunopathol. 57:242-249.
12. Liew, F., and C. O'Donnell. 1993. Immunology of leishmaniasis. Adv. Parasitol. 32:162-192.
13. Reiner, S.L., and R.M. Locksley. 1995. The regulation of immunity to Leishmania major. Ann. Rev. Immunol. 13:151-177.
14. Doherty, T., R. Kastelein, S. Menon, and R.L. Coffman. 1993. Modulation of murine macrophage function by IL-13. J. Immunol. 151:7151-7160.
15. Barral-Netto, M., A. Barral, C. Brownell, Y. Skeiky, D. Twardizk, and S. Reed. 1992. Transforming growth factor-β in leishmanial infection. Science (Wash. DC). 257:545-548.
16. Heinzel, F.P., M.D. Sadick, S.S. Mutha, and R.M. Locksley. 1991. Production of interferon-γ, interleukin-2, interleukin-4, and interleukin-10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl. Acad. Sci. USA. 88:7011-7015.
17. Scharton-Kersten, T., L. Afonso, M. Wysocka, G. Trinchieri, and P. Scott. 1995. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154:5320-5330.
18. Alfonso, L., and P. Scott. 1993. Immune response associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun, 61:2952-2959.
19. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the marine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63:4894-4899.
20. Bradley, D.J., B.A. Taylor, J. Blackwell, E.P. Evans, and J. Freeman. 1979. Regulation of Leishmania populations within the host. III. Mapping of the locus controlling susceptibility to visceral leishmaniasis in the mouse. Clin. Exp. Immunol. 37:7-17.
21. Crocker, P., J.M. Blackwell, and D.J. Bradley. 1984. Expression of the natural resistance gene Lsh in resident liver macrophages, Infect. Immun. 43:1033-1040.
22. Murray, H.W., J.J. Stern, K. Weite, B.Y. Rubin, S.M. Carriero, and C.F. Nathan. 1987. Experimental visceral leishmaniasis; production of interleukin-2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin-2 and interferon-γ. J. Immunol. 138:2290-2296.
23. Kaye, P.M., A.J. Curry, and J.M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146: 2764-2770.
24. Murray, H.W., J. Hariprashad, D. McDermott, and M.Y. Stoeckle. 1996. Multiple host defense defects in the failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection. Infect. Immun. 62:161-166.
25. Wilson, M.E., M. Sandor, A.M. Blum, B. Younbg, A. Metwali, D. Elliot, R.G. Lynch, and J.V. Weinstock. 1996. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
26. Miralles, G.D., M.Y. Stoeckle, D.F. McDermott, F.D. Finkelman, and H.W. Murray. 1994. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058-1062.
27. Squires, K.E., R.D. Schreiber, J.J. McElrath, B.Y. Rubin, S.L. Anderson, and H.W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous interferon-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249.
28. Murray, H.W., and J. Hariprashad. 1995. Endogenous and exogenous IL-12 in experimental visceral leishmaniasis: effect of anti-IL-12 and treatment with IL-12 plus antimony. J. Investing. Med. 43:413a. (Abstr.)
29. Kopf, M., G. Le Gros, M. Bachmann, M.C. Lamers, H. Bluethmann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature (Lond.). 362:245-247.
30. Muller, W., R. Kuhn, and K. Rajewsky. 1991. Major histocompatibility complex class II hyperexpression on B cells in interleukin 4-transgenic mice does not lead to B cell proliferation and hypergammaglobulinemia. Eur. J. Immunol. 21: 921-925.
31. Leal, L.M., R. Kuhn, W. Muller, and F.Y. Liew. 1993. Interleukin-4 transgenic mice of resistant background are sus ceptibie to Leishmania major infection. Eur. J. Immunol. 23: 566-569.
32. Finkelman, F., K. Madden, S. Morris, I. Katoma, and C. Maliszewki. 1993. Anti-cytokine antibodies as carrier proteins; prolongation of in vitro effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151:1235-1242.
33. Heinzel, P.P., R.M. Rerko, F. Ahmed, and E. Perlman. 1995. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:730-739.
34. Sypek, J., C. Chung, S. Mayor, S. Goldman, D. Sieburth, S. Wolf, and R. Schwab. 1993. Resolution of cutaneous leishmaniasis: IL-12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797-1802.
35. Liew, F.Y., C. Hale, and J.G. Howard. 1985. Prophylactic immunixation against experimental leishmaniasis. IV. Subcutaneous immunization prevents induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.
36. Abrams, J.S., M.G. Roncarolo, H. Yssel, U. Anderson, G.J. Gleich, and J.E. Silver. 1992. Strategies of anticytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol. Rev. 127:5-16.
37. Murray, H.W., and J. Hariprashad. 1995. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp. Med. 181: 387-391.
38. Murray, H.W. 1990. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis. J. Infect. Dis. 161:992-994.
39. Heinzel, F., D. Schoenhaut, L. Rosser, and M. Gately. 1993. Recombinant interleukin-12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505-1509.
40. Coffman, R.L., and J. Carty. 1986. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-γ. J. Immunol. 136:949-954.
41. Mocci, S., and R.L. Coffman. 1995. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4. J. Immunol. 154:3779-3787.
42. Chatelain, R., K. Varkila, and R.L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182-1187.
43. Sadick, M.D., N. Street, T.R. Mosmann, and R.M. Locksley. 1991. Cytokine regulation of murine leishmaniasis: interleukin 4 is not sufficient to mediate progressive disease in resistant C57BL/6 mice. Infect. Immun. 59:4710-4712.
44. Trinchieri, G. 1995. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 33:251-262.
45. Heinzel, F.P., M.D. Sadick, B.J. Holaday, R.L. Coffman, and R.M. Locksley. 1989. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leshmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:59-72.
46. Bretscher, P., G. Wei, J. Menon, and H. Bielefeldt. 1992. Establishment of stable cell-mediated immunity that makes sus ceptible mice resistant to Leishmania major. Science (Wash. DC), 257:539-542.
47. McElrath, J.J., H.W. Murray, and Z.A. Cohn. 1988. The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp, Med. 167:1927-1937.
48. Murray, H.W., J. Hariprashad, B. Aguero, and H. Yeganeyi. 1995. Intracellular antimicrobial response of T cell-deficient host to cytokine therapy: IFN-γ in experimental visceral leishmaniasis in nude mice. J. Infect. Dis. 171:1309-1314.
49. Ghalib, H., J. Whitle, M. Kubin, F. Hashim, K. Grabstein, G. Trinchieri, and S. Reed. 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154:4623-4629.
50. Powrie, F., S. Menon, and R.L. Coffman. 1993. IL-4 and IL-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23:2223-2229.
51. Sadick, M.D., F.P. Heinzel, B.J. Holaday, R.S. Dawkins, and R.M. Locksley. 1990. Cure of murine leishmaniasis with anti-interleukin-4 monoclonal antibody. Evidence for a T cell-dependent, interferon-γ-independent mechanism. J. Exp. Med. 171:115-127.
52. Nabors, G.S., L. Afonso, J. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA. 92:3142-3146.
53. Wynn, T., I. Oswald, A. Cheever, and A. Sher. 1994. Endogenous interleukin 12 regulates granuloma formation induced by Schistosoma mansoni and exogenous IL-12 both inhibits and immunizes against egg pathology. J. Exp. Med. 179:1551-1561.
54. Gazzinelli, R., N. Giese, and H. Morse. 1994. In vivo treatment with IL-12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome. J. Exp. Med. 180:2199-2208.
55. Urban, J., K. Madden, A. Cheever, P. Trutta, and F. Finkelman. 1993. IFN inhibits inflammatory responses and protective immunity in mice infected with the nematode parasite, Nippostrongylus. J. Immunol. 151:7086-7094.
56. Pearlman, E., F. Hazlett, F. Heinzel, S. Wolf, and J. Kazura. 1994. IL-12 modulation of T helper responses to the filarial helminth, Brugia malayi. Am. J. Trop. Med. Hyg. 51:221a. (Abstr.).
57. Renz, H., K. Jujo, K. Bradley, J. Domenico, E. Gelfand, and D. Leung. 1993. Enhanced IL-4 production and IL-4 receptor expression in atopic dermatitis and their modulation by interferon-gamma. J. Invest. Dermatol. 99:403-408.
58. + T lymphocytes. J. Immunol. 155:111-117.
59. Donnelly, R., S.L. Freeman, and M.P. Hayes. 1995. Inhibition of IL-10 expression by IFN-γ upregulates transcription of TNF-α in human monocytes. J. Immunol. 155:1420-1427.
60. Sundar, S., and H.W. Murray. 1995. Effect of treatment with interferon-γ alone in Indian visceral leishmaniasis. J. Infect. Dis. 172:1627-1630.